Authors: Bellone, Stefania; Pecorelli, Sergio; Cannon, Martin J; Santin, Alessandro D

Source: Expert Review of Anticancer Therapy, Volume 7, Number 10, October 2007 , pp. 1473-1486(14)

Publisher: Expert Reviews

Abstract:

Cervical cancer is the second leading cause of cancer death among women worldwide and remains an important health problem for women, especially in underserved and minority groups in industrially developed nations. Although radical surgery and radiotherapy represent effective modalities of treatment for invasive cervical cancer, up to 35% of these patients overall will develop recurrent/metastatic disease for which treatment results remain poor. Novel therapeutic strategies that are effective in reducing the risk of recurrence/metastatic disease are still needed desperately. Human papillomavirus (HPV) infection represents the most important risk factor for the development of cervical dysplasia and cervical cancer. Since HPVE6 and E7 oncoproteins are constantly expressed in these lesions, these foreign proteins represent ideal tumor-specific target antigens for immunotherapy of cervical cancer. Recently, the recognition of dendritic cells (DC) as powerful antigen-presenting cells, capable of inducing primary T-cell responses in vitro and in vivo, has generated widespread interest in DC-based immunotherapy of several human malignancies. This review summarizes the therapeutic clinical trials and the different preclinical research strategies that are under investigation, with a particular emphasis on the use of autologous DC-pulsed HPV16 or 18 E7 oncoproteins as therapeutic vaccines against cervical cancer.

Keywords: cervical cancer; cytotoxic T lymphocyte; dendritic cell; E7; human papillomavirus; immunosuppression; immunotherapy

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737140.7.10.1473

Publication date: 2007-10-01

More about this publication?

• Expert Review of Anticancer Therapy provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Oncology ,  Pharmacology
• By this author: Bellone, Stefania ;  Pecorelli, Sergio ;  Cannon, Martin J ;  Santin, Alessandro D

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers